|Series A, 9/07 |
|Series B, 5/09 |
Bessemer Venture Partners
Devon Park BioVentures
MPM Bio IV NVS Strategic Fund
Vectis Healthcare & Life Sciences Fund
|Venture Round, 8/11 ||$15.2M|
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.
The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.
Proteon Therapeuticsâ€™ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.
The companyâ€™s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).